Deltyba
(Delamanid)Phase 3Small molecule
OtsukaDelamanid is used to treat drug-resistant tuberculosis, a severe lung infection that doesn't respond to standard antibiotics. It works by stopping the growth of tuberculosis bacteria in the body.[1] Deltyba is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Deltyba is one of 69 small molecule programs targeting Mycobacterium infection. It is currently in Phase 3.
7
Indications
29
Total Trials
12
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Rifadin
SanofiPhase 3
Deltyba
OtsukaPhase 3
Sitafloxacin
Daiichi SankyoPhase 3
Tenofovir DF
GileadPhase 3
BCG Vaccine
GGynecologic Oncology Group
Phase 3
Isoniazid and Rifapentine
CCenters for Disease Control and Prevention
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Gamtbvac
GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Phase 3
Tivicay
GSKPreclinical
Biktarvy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tuberculosis7 trials
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled
Show 4 more trials
A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03141060·37 enrolled
Pulmonary Tuberculosis4 trials
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Active, not recruiting·CCenters for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled
Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis
Unknown status·—·Phase 2·NCT06224036·52 enrolled
Show 1 more trial
Drug3 trials
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
Active, not recruiting·—·Phase 2·NCT05556746·94 enrolled
Linezolid Dosing Strategies in Drug-Resistant TB
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05007821·138 enrolled
Efficacy2 trials
Multidrug-Resistant Tuberculosis2 trials
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT03568383·5,832 enrolled
11 more indications
Effectiveness1 trial
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Unknown status·—·Phase 4·NCT04421495·608 enrolled
Pregnancy1 trial
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled
Drug-Resistant Tuberculosis1 trial
RR-TB1 trial
Fluoroquinolone1 trial
Tuberculosis, Multidrug-Resistant1 trial
Pulmonary TB1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Delamanid. EMBL-EBI & Wellcome Sanger Institute.
- [4]